Page last updated: 2024-10-20

pyridoxine and Erythema

pyridoxine has been researched along with Erythema in 9 studies

4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).

Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.

Research Excerpts

ExcerptRelevanceReference
"The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)."7.68Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990)
"Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis."5.14Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010)
"The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)."3.68Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19902 (22.22)18.7374
1990's3 (33.33)18.2507
2000's2 (22.22)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jeung, HC1
Chung, HC1
Chalermchai, T1
Tantiphlachiva, K1
Suwanrusme, H1
Voravud, N1
Sriuranpong, V1
von Moos, R1
Thuerlimann, BJ1
Aapro, M1
Rayson, D1
Harrold, K1
Sehouli, J1
Scotte, F1
Lorusso, D1
Dummer, R1
Lacouture, ME1
Lademann, J1
Hauschild, A1
Rossi, D1
Catalano, G1
Vukelja, SJ1
Baker, WJ1
Burris, HA1
Keeling, JH1
Von Hoff, D1
Tanaka, M1
Niizeki, H1
Shimizu, S1
Miyakawa, S1
Fabian, CJ1
Molina, R1
Slavik, M1
Dahlberg, S1
Giri, S1
Stephens, R1
Schmutz, JL1
Cuny, JF1
Trechot, P1
Weber, M1
Beurey, J1
Ishibashi, A1
Hirano, K1
Nishiyama, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028]Phase 2100 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for pyridoxine and Erythema

ArticleYear
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col

2010

Other Studies

8 other studies available for pyridoxine and Erythema

ArticleYear
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fl

2010
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:6

    Topics: Adrenal Cortex Hormones; Dermatologic Agents; Doxorubicin; Drug Eruptions; Erythema; Foot Dermatoses

2008
Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Clinical Trials as Topic; Doxorubicin; Erythema;

2007
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
    Journal of the National Cancer Institute, 1993, Sep-01, Volume: 85, Issue:17

    Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Hu

1993
Photoallergic drug eruption due to pyridoxine hydrochloride.
    The Journal of dermatology, 1996, Volume: 23, Issue:10

    Topics: Aged; Dermatitis, Photoallergic; Drug Eruptions; Erythema; Humans; Male; Patch Tests; Pyridoxine; Th

1996
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
    Investigational new drugs, 1990, Volume: 8, Issue:1

    Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose

1990
[Drug-induced pellagroid erythema. A case of pellagroid erythema caused by isoniazide].
    Annales de dermatologie et de venereologie, 1987, Volume: 114, Issue:4

    Topics: Antineoplastic Agents; Erythema; Ethionamide; Female; Humans; Isoniazid; Middle Aged; Monoamine Oxid

1987
Photosensitive dermatitis due to pyritinol.
    Archives of dermatology, 1973, Volume: 107, Issue:3

    Topics: Administration, Oral; Biopsy; Dermatitis, Exfoliative; Drug Eruptions; Erythema; Humans; Lichen Plan

1973